Login to Your Account



Zerenex Phase III Data Wow; Keryx Hits 52-Week High

By Marie Powers
Staff Writer

Monday, January 28, 2013
in_the_clinic.jpg

Three weeks ago, Keryx Biopharmaceuticals Inc. CEO Ron Bentsur faced tough questions at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco about continuing delays in reporting long-term Phase III data on Zerenex (ferric citrate) for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis.

On Monday, those doubts were laid to rest when the company reported the compound met its primary and all key secondary endpoints in the study, sending shares (NASDAQ:KERX) to a 52-week high of $6.86.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription